
|Videos|June 16, 2016
Potential Impact of Regorafenib in Patients With HCC
Author(s)Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential impact that regorafenib (Stivarga) could have on the treatment landscape of hepatocellular carcinoma (HCC).






































